Skip to main content
Premium Trial:

Request an Annual Quote

Poniard to Use AltheaDx Platform to ID Molecular Signatures

NEW YORK (GenomeWeb News) – Poniard Pharmaceuticals said today that it will use AltheaDx’s Express Pathway program to identify molecular signatures that may be correlated to platinum resistance.
The South San Francisco, Calif.-based biopharmaceutical firm is developing platinum-based therapies for cancer and has produced a new agent designed to overcome platinum resistance. It plans to use AltheaDx’s high-throughput gene expression platform to develop molecular signatures of platinum resistance that may enable the prediction of clinical response to the new drug — called picoplatin — and improve patient outcomes.
Terms of the collaboration were not disclosed.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.